Ian E. Smith
YOU?
Author Swipe
View article: Incidence and prevalence of obstructive sleep apnoea and narcolepsy in the UK: a population-based descriptive study
Incidence and prevalence of obstructive sleep apnoea and narcolepsy in the UK: a population-based descriptive study Open
Obstructive sleep apnoea and narcolepsy affect approximately 4.8% and 0.047% of the UK population, respectively. We do not know how many people have been diagnosed or how this varies over time and by demographic factors. We therefore condu…
View article: Potency-optimized CD28-activating bispecific antibody for the targeted treatment of Nectin-4 positive cancers
Potency-optimized CD28-activating bispecific antibody for the targeted treatment of Nectin-4 positive cancers Open
Background T-cell costimulation is crucial for an effective and sustained antitumor immune response, and inadequate expression of costimulatory ligands within tumors can impair T-cell function. Bispecific antibodies (bsAbs) targeting a tum…
View article: Trends and variation in issuance of high‐cost narcolepsy drugs by <scp>NHS</scp> England organisations and regions from 2019 to 2022
Trends and variation in issuance of high‐cost narcolepsy drugs by <span>NHS</span> England organisations and regions from 2019 to 2022 Open
Summary Clinicians and people with narcolepsy report varied access to higher‐cost narcolepsy treatments in England associated with variations in national and local commissioning. There are no publicly available data quantifying use of thes…
View article: Comparison of mathematically arterialised venous blood gas sampling with arterial, capillary, and venous sampling in adult patients with hypercapnic respiratory failure: a single-centre longitudinal cohort study
Comparison of mathematically arterialised venous blood gas sampling with arterial, capillary, and venous sampling in adult patients with hypercapnic respiratory failure: a single-centre longitudinal cohort study Open
Background Accurate arterial blood gas (ABG) analysis is essential in the management of patients with hypercapnic respiratory failure, but repeated sampling requires technical expertise and is painful. Missed sampling is common and has a n…
View article: Supplementary Table 1 from Immunohistochemical Phenotype of Breast Cancer during 25-Year Follow-up of the Royal Marsden Tamoxifen Prevention Trial
Supplementary Table 1 from Immunohistochemical Phenotype of Breast Cancer during 25-Year Follow-up of the Royal Marsden Tamoxifen Prevention Trial Open
Immunohistochemical analysis of biomarkers.
View article: Data from Immunohistochemical Phenotype of Breast Cancer during 25-Year Follow-up of the Royal Marsden Tamoxifen Prevention Trial
Data from Immunohistochemical Phenotype of Breast Cancer during 25-Year Follow-up of the Royal Marsden Tamoxifen Prevention Trial Open
The randomized, double-blinded Royal Marsden Tamoxifen Breast Cancer Prevention Trial in healthy high-risk women started in 1986 and is still blinded. Eligible participants (n = 2,471) were randomly assigned to tamoxifen (20 mg/d) or place…
View article: Data from Immunohistochemical Phenotype of Breast Cancer during 25-Year Follow-up of the Royal Marsden Tamoxifen Prevention Trial
Data from Immunohistochemical Phenotype of Breast Cancer during 25-Year Follow-up of the Royal Marsden Tamoxifen Prevention Trial Open
The randomized, double-blinded Royal Marsden Tamoxifen Breast Cancer Prevention Trial in healthy high-risk women started in 1986 and is still blinded. Eligible participants (n = 2,471) were randomly assigned to tamoxifen (20 mg/d) or place…
View article: Supplementary Table 1 from Immunohistochemical Phenotype of Breast Cancer during 25-Year Follow-up of the Royal Marsden Tamoxifen Prevention Trial
Supplementary Table 1 from Immunohistochemical Phenotype of Breast Cancer during 25-Year Follow-up of the Royal Marsden Tamoxifen Prevention Trial Open
Immunohistochemical analysis of biomarkers.
View article: Data from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
Data from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers Open
Purpose:Aromatase inhibitor (AI) treatment is the standard of care for postmenopausal women with primary estrogen receptor–positive breast cancer. The impact of duration of neoadjuvant endocrine therapy (NET) on molecular characteristics i…
View article: Supplementary Figure from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
Supplementary Figure from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers Open
Supplementary Figure from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
View article: Supplementary Table 3 from Molecular Profiling of Aromatase Inhibitor–Treated Postmenopausal Breast Tumors Identifies Immune-Related Correlates of Resistance
Supplementary Table 3 from Molecular Profiling of Aromatase Inhibitor–Treated Postmenopausal Breast Tumors Identifies Immune-Related Correlates of Resistance Open
PDF file - 81K, IPA analysis and genes in the inflammatory immune response signature.
View article: Supplementary Figure S3a-x from Changes in Expression of Genes Representing Key Biologic Processes after Neoadjuvant Chemotherapy in Breast Cancer, and Prognostic Implications in Residual Disease
Supplementary Figure S3a-x from Changes in Expression of Genes Representing Key Biologic Processes after Neoadjuvant Chemotherapy in Breast Cancer, and Prognostic Implications in Residual Disease Open
Kaplan-Meier curves with probability of relapse, with genes divided into tertiles for all 24 genes for the end-point TTR for (a) ACACB (b) ALDHA1 (c) AURKA (d) BCL2 (e) BCL2L1 (f) CD3D (g) CD44 (h) CXCL14 (i) DECORIN (j) DUSP4 (k) ERBB2 (l…
View article: Supplementary Table 5 from Molecular Profiling of Aromatase Inhibitor–Treated Postmenopausal Breast Tumors Identifies Immune-Related Correlates of Resistance
Supplementary Table 5 from Molecular Profiling of Aromatase Inhibitor–Treated Postmenopausal Breast Tumors Identifies Immune-Related Correlates of Resistance Open
PDF file - 46K, Prediction analysis of correlated genes.
View article: Supplementary Figure 3 from Molecular Profiling of Aromatase Inhibitor–Treated Postmenopausal Breast Tumors Identifies Immune-Related Correlates of Resistance
Supplementary Figure 3 from Molecular Profiling of Aromatase Inhibitor–Treated Postmenopausal Breast Tumors Identifies Immune-Related Correlates of Resistance Open
PDF file - 87K, Lymphocytic infiltration in tumours.
View article: Supplementary Figure 1 from Noninvasive Detection of <i>HER2</i> Amplification with Plasma DNA Digital PCR
Supplementary Figure 1 from Noninvasive Detection of <i>HER2</i> Amplification with Plasma DNA Digital PCR Open
PDF File - 1282, Digital PCR assay for HER2 on 384 well microplates.
View article: Supplementary Figure 5 from Noninvasive Detection of <i>HER2</i> Amplification with Plasma DNA Digital PCR
Supplementary Figure 5 from Noninvasive Detection of <i>HER2</i> Amplification with Plasma DNA Digital PCR Open
PDF File - 883K, Bio-informatic comparison of different reference probes.
View article: Supplementary Figure 4 from Noninvasive Detection of <i>HER2</i> Amplification with Plasma DNA Digital PCR
Supplementary Figure 4 from Noninvasive Detection of <i>HER2</i> Amplification with Plasma DNA Digital PCR Open
PDF File - 438K, HER2 : EFTUD2 copy number ratio in validation cohort.
View article: Supplementary Figure S2 from Changes in Expression of Genes Representing Key Biologic Processes after Neoadjuvant Chemotherapy in Breast Cancer, and Prognostic Implications in Residual Disease
Supplementary Figure S2 from Changes in Expression of Genes Representing Key Biologic Processes after Neoadjuvant Chemotherapy in Breast Cancer, and Prognostic Implications in Residual Disease Open
Correlation coefficient matrix between of genes and IHC ER, PgR, and Ki67. Shades of blue indicate a positive correlation, and shades of orange a negative correlation.
View article: Data from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
Data from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers Open
Purpose:Aromatase inhibitor (AI) treatment is the standard of care for postmenopausal women with primary estrogen receptor–positive breast cancer. The impact of duration of neoadjuvant endocrine therapy (NET) on molecular characteristics i…
View article: Supplementary Methods from Noninvasive Detection of <i>HER2</i> Amplification with Plasma DNA Digital PCR
Supplementary Methods from Noninvasive Detection of <i>HER2</i> Amplification with Plasma DNA Digital PCR Open
PDF File - 177K, Supplementary methods, tables, and figures legends.
View article: Supplementary Table S1 from Changes in Expression of Genes Representing Key Biologic Processes after Neoadjuvant Chemotherapy in Breast Cancer, and Prognostic Implications in Residual Disease
Supplementary Table S1 from Changes in Expression of Genes Representing Key Biologic Processes after Neoadjuvant Chemotherapy in Breast Cancer, and Prognostic Implications in Residual Disease Open
List of the selected genes, the associated biological process, prognostic and/or treatment predictive value in previous studies, and biological function. Apart from the 22 gene in the list below, the clinically established prognostic and t…
View article: Supplementary methods from Early Enrichment of ESR1 Mutations and the Impact on Gene Expression in Presurgical Primary Breast Cancer Treated with Aromatase Inhibitors
Supplementary methods from Early Enrichment of ESR1 Mutations and the Impact on Gene Expression in Presurgical Primary Breast Cancer Treated with Aromatase Inhibitors Open
E2F activation metagene & Fluorescence activated cell sorting
View article: Supplementary Figure 1 from Molecular Profiling of Aromatase Inhibitor–Treated Postmenopausal Breast Tumors Identifies Immune-Related Correlates of Resistance
Supplementary Figure 1 from Molecular Profiling of Aromatase Inhibitor–Treated Postmenopausal Breast Tumors Identifies Immune-Related Correlates of Resistance Open
PDF file - 109K, Derivation of samples for microarray analysis.
View article: Supplementary Data from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
Supplementary Data from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers Open
Supplementary Data from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
View article: Supplementary Data from A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer
Supplementary Data from A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer Open
Supplementary Figures S1-S3; Supplementary Tables S1-S3.
View article: Supplementary Table S3 from Changes in Expression of Genes Representing Key Biologic Processes after Neoadjuvant Chemotherapy in Breast Cancer, and Prognostic Implications in Residual Disease
Supplementary Table S3 from Changes in Expression of Genes Representing Key Biologic Processes after Neoadjuvant Chemotherapy in Breast Cancer, and Prognostic Implications in Residual Disease Open
Association between DUSP4 expression and Ras-ERK pathway proteins measured by reverse-phase protein arrays (RPPA) in 633 breast tumours from TCGA
View article: Supplementary Tables from Early Enrichment of ESR1 Mutations and the Impact on Gene Expression in Presurgical Primary Breast Cancer Treated with Aromatase Inhibitors
Supplementary Tables from Early Enrichment of ESR1 Mutations and the Impact on Gene Expression in Presurgical Primary Breast Cancer Treated with Aromatase Inhibitors Open
Supplementary Table S1-S12